European Industry Leaders From Energy, Mobility & Sustainability Join Energy Impact Partners Global Innovation Platform
Energy Impact Partners (EIP), the global investment platform leading the transition to a sustainable energy future, has announced the formation of a European Coalition to advance new technologies and tackle climate change. EIP works closely with its investors -- more than 25 of the largest, most innovative, and environmentally conscious energy and industrial companies as well as climate-investors -- to develop cutting-edge solutions across four continents through a unique collaborative model. The EIP network collaborates by sharing insights, investing in innovative and transformative businesses, and then amplifying entrepreneurs' growth through dedicated partnerships.
“Our proven model is based on collaboration, learning, and sharing -- and it can only thrive with the right partners. We are thrilled to see some of the most innovative European players and AGL, the leading utility in Australia, join our mission as founding members.”
- Matthias Dill, CEO & Managing Director Europe for Energy Impact Partners
“Energy Impact Partners’ unique set up with strong focus in collaboration, partnerships and creating valuable insights is an efficient way to strengthen Fortum’s presence in global energy innovation ecosystem. As a partner, Fortum will gain early access to new business models and solutions in both European and US markets. The aim is to be in the frontlines in finding, piloting and scaling the innovations with potential to change the energy sector as we know it.”
- Arun Aggarwal, SVP of Fortum’s Business Technology unit
The newly formed European Coalition complements EIP’s proven North American model with investors from four continents and provide unparalleled insights for its partners and global market access for its portfolio. The coalition encompasses over 25 industrials with revenues exceeding the combined sales of Amazon, Facebook and Google and access to more than 200 million households.
“We look forward to learning, collaborating and defining the energy landscape of the future. Innovation is a global business and by collaborating we can tackle future challenges more effectively.”
- Urban Keussen, CTO of EWE and Chairman of the European Coalition
“To halt climate change, we need to make an impact now. By bringing together industry, capital and visionaries we have the best chance to succeed. We look forward to working with EIP in Norway and beyond.”
- Siri Kalvig, CEO of Nysno Climate Investments and Chair of EIP’s ESG Committee
"Climate related technologies are progressing at an impressive pace, both in Europe and globally. By partnering with EIP we get the chance to both contribute to the development and learn from the achievements of other interesting companies. The investment strengthens our position towards new energy related markets and ideas and helps us stay in the forefront in terms of smarter and more climate friendly energy solutions."
- Ståle Gjersvold, CEO at TrønderEnergi
"AGL is happy to extend our valued partnership with EIP. We have been impressed with the EIP model and we’re confident it will be successful in the European markets.”
- Simon Moorfield, Executive General Manager at AGL
About Energy Impact Partners
Energy Impact Partners (EIP) is a global investment platform leading the transition to a sustainable energy future. EIP brings together entrepreneurs and the world's most forward-looking energy and industrial companies to advance innovation. With over $1.5 billion in assets under management, EIP invests globally across venture, growth, credit and infrastructure – and has a team of more than 45 professionals based in its offices in New York, San Francisco, Palm Beach, London, Cologne and soon Oslo. For more information on EIP, please visit www.energyimpactpartners.com. EIP’s network has over 25 partners including Southern Company, Xcel Energy, Fortis, Duke Energy, Tennessee Valley Authority Asset Retirement Trust, Emera, APS, NYSNO, TronderEnergi, EWE, Enterprise Holdings, Fortum, Evergy, OG&E, Ameren, TC Energy, Alliant Energy, Avista, National Grid, PTT, TEPCO, AGL, 1898&co and MGE.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200716005643/en/
Contact information
EU Press
Antonella Scimemi
Burlington
antonella@burlington.cc
+44 (0)7530 815 018
U.S. Press
Tori McDonnell
Silverline Communications
tori@teamsilverline.com
01-703-338-2362
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA ® Commercialization in Central and Eastern Europe7.1.2026 09:30:00 EET | Press release
Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom